Phase II trials of cardiac imaging agent BFPET underway

01/3/2013 | Yahoo

FluoroPharma said Phase II trials of its BFPET imaging agent for chronic coronary artery disease have started at Massachusetts General Hospital. In this current study, the fluorine-18-labeled tracer will be compared with Rb-82 and/or other SPECT agents such as sestamibi.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA